星空体育官方入口网站网址大全-登录入口官网

#RAF抑制剂#

9篇内容 | 820人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1936832, encodeId=306319368323d, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, objectTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, objectType=article, longId=727754, objectId=ef63e277540f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef63e277540f, replyNumber=0, likeNumber=72, createdTime=2022-09-03, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef63e277540f, moduleTitle=Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ef63e277540f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1936831, encodeId=1b43193683127, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, objectTitle=复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元, objectType=article, longId=209533, objectId=155e209533de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=155e209533de, replyNumber=0, likeNumber=68, createdTime=2021-12-09, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=155e209533de, moduleTitle=复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=155e209533de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1936829, encodeId=adfe1936829ac, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, objectTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, objectType=article, longId=195394, objectId=51fd195394e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51fd195394e1, replyNumber=0, likeNumber=71, createdTime=2020-06-15, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51fd195394e1, moduleTitle=BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=51fd195394e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1936830, encodeId=648e193683046, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, objectTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, objectType=article, longId=200028, objectId=1381200028b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1381200028b8, replyNumber=0, likeNumber=66, createdTime=2021-02-10, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1381200028b8, moduleTitle=Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1381200028b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1936826, encodeId=5b67193682676, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, objectTitle=璧辰医药BRAF抑制剂ABM-1310获美国FDA临床试验许可, objectType=article, longId=183896, objectId=82f1183896b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82f1183896b9, replyNumber=0, likeNumber=52, createdTime=2020-10-26, rootId=0, userName=一叶知秋, userId=30bd35, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82f1183896b9, moduleTitle=璧辰医药BRAF抑制剂ABM-1310获美国FDA临床试验许可, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=82f1183896b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1936828, encodeId=369319368286d, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, objectTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, objectType=article, longId=191946, objectId=1e43191946c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e43191946c0, replyNumber=0, likeNumber=70, createdTime=2020-04-11, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e43191946c0, moduleTitle=辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1e43191946c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1936827, encodeId=2a6c193682ea9, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, objectTitle=BRAF抑制剂在儿童低级别胶质瘤中显示出令人欣喜的结果, objectType=article, longId=186510, objectId=455918651038, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=455918651038, replyNumber=0, likeNumber=78, createdTime=2020-05-17, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=455918651038, moduleTitle=BRAF抑制剂在儿童低级别胶质瘤中显示出令人欣喜的结果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=455918651038)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1936825, encodeId=d58b193682559, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, objectTitle=CLIN CHEM：黑色素瘤患者血浆中循环肿瘤DNA的液体分析用于伴随诊断和BRAF抑制剂治疗的监测, objectType=article, longId=138830, objectId=1e7b1388303f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e7b1388303f, replyNumber=0, likeNumber=70, createdTime=2018-08-31, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e7b1388303f, moduleTitle=CLIN CHEM：黑色素瘤患者血浆中循环肿瘤DNA的液体分析用于伴随诊断和BRAF抑制剂治疗的监测, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1e7b1388303f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1936824, encodeId=6d6e1936824ce, content=<a href='/topic/show?id=0c3f1509582' target=_blank style='color:#2F92EE;'>#RAF抑制剂#</a>, objectTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, objectType=article, longId=137007, objectId=d64a13e007c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64a13e007c3, replyNumber=0, likeNumber=78, createdTime=2018-09-15, rootId=0, userName=ms1490123962508630, userId=ca772500164, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64a13e007c3, moduleTitle=诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d64a13e007c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

RAF抑制剂

2020-05-29

ms1490123962508630 (审核中...)

前往app查看评论内容

#RAF抑制剂#

Clinical Colorectal Cancer:BRAF抑制剂encorafenib(康奈非尼)联合西妥昔单抗治疗经治的BRAFV600E突变转移性结直肠癌的疗效

2022-09-03

ms1490123962508630 (审核中...)

前往app查看评论内容

#RAF抑制剂#

复宏汉霖获润新生物BRAF抑制剂权益，合作金额**超10亿元

2021-12-09

ms1490123962508630 (审核中...)

前往app查看评论内容

#RAF抑制剂#

BRAF抑制剂Braftovi获欧洲药品管理局批准，与EGFR抗体Erbitux联合治疗结直肠癌

2020-06-15

ms1490123962508630 (审核中...)

前往app查看评论内容

#RAF抑制剂#

Clin Cancer Res：靶向细胞外基质重构可恢复BRAFi耐药性黑色素瘤对BRAF抑制剂的敏感性

2021-02-10

一叶知秋 (审核中...)

前往app查看评论内容

#RAF抑制剂#

璧辰医药BRAF抑制剂ABM-1310获美国FDA临床试验许可

2020-10-26

ms1490123962508630 (审核中...)

前往app查看评论内容

#RAF抑制剂#

辉瑞114亿美元收购的BRAF抑制剂Braftovi，获FDA批准与西妥昔单抗联合治疗结直肠癌

2020-04-11

ms1490123962508630 (审核中...)

前往app查看评论内容

#RAF抑制剂#

BRAF抑制剂在儿童低级别胶质瘤中显示出令人欣喜的结果

2020-05-17

ms1490123962508630 (审核中...)

前往app查看评论内容

#RAF抑制剂#

CLIN CHEM：黑色素瘤患者血浆中循环肿瘤DNA的液体分析用于伴随诊断和BRAF抑制剂治疗的监测

2018-08-31

ms1490123962508630 (审核中...)

前往app查看评论内容

#RAF抑制剂#

诺华BRAF抑制剂与MEK抑制剂获FDA批准联合靶向治疗黑色素瘤

2018-09-15

科室
- - 订阅+
  - 更多科室
工具
服务